公开(公告)号：US20050118166A1

公开(公告)日：2005-06-02

申请号：US10618298

申请日：2003-07-11

申请人： Michael Yellin ,  Seth Lederman ,  Leonard Chess ,  Mihail Karpusas ,  David Thomas

发明人： Michael Yellin ,  Seth Lederman ,  Leonard Chess ,  Mihail Karpusas ,  David Thomas

IPC分类号： A61K38/00 ,  C07K14/705 ,  C07K16/28 ,  G01N33/50 ,  G01N33/576 ,  A61K39/395

CPC分类号： G01N33/576 ,  A61K38/00 ,  C07K14/70575 ,  C07K14/70578 ,  C07K16/2875 ,  G01N33/5047 ,  G01N2333/70578 ,  Y02A50/401

摘要： Activation of cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Activation of cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Conditions dependent on CD4O ligand-induced activation of CD40-bearing cells are treated.

摘要翻译： 通过使细胞与能够抑制CD40配体和细胞之间的相互作用的试剂以有效抑制细胞活化的量接触来抑制CD40配体在其细胞表面上带有CD40的细胞的活化。 通过向受试者施用能够抑制CD40配体和细胞之间的相互作用的试剂，以有效抑制细胞活化的量来抑制受试者中CD40配体在其表面上带有CD40的细胞的活化。 治疗依赖于CD4O配体诱导的携带CD40细胞的活化的病症。

公开(公告)号：US20080050369A1

公开(公告)日：2008-02-28

申请号：US11698692

申请日：2007-01-25

申请人： Michael Yellin ,  Leonard Chess ,  Mihail Karpusas ,  David Thomas

发明人： Michael Yellin ,  Leonard Chess ,  Mihail Karpusas ,  David Thomas

IPC分类号： A61K39/395 ,  A61P1/02

CPC分类号： C07K14/70575 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70578 ,  C07K16/2875 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2319/00 ,  G01N33/5061 ,  G01N2333/70596

摘要： Activation of smooth muscle cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the smooth muscle cells with an anti-T-BAM (CD40L) antibody capable of inhibiting the interactions between CD40 ligand and the CD40-bearing smooth muscle cells, in an amount effective to inhibit activation of the smooth muscle cells. Activation of smooth muscle cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an anti-T-BAM (CD40L) antibody capable of inhibiting the interaction between CD40 ligand and the smooth muscle cells, in an amount effective to inhibit activation of the cells. Conditions dependent on CD40 ligand-induced activation of CD40-bearing cells smooth muscle cells are treated, in particular inflammatory bowel disease.

摘要翻译： 通过使平滑肌细胞与能够抑制CD40配体和携带CD40的平滑肌细胞之间的相互作用的抗T-BAM（CD40L）抗体接触来抑制CD40配体在其细胞表面上带有CD40的平滑肌细胞的活化， 其量有效抑制平滑肌细胞的活化。 通过向受试者施用能够抑制CD40配体和平滑肌细胞之间的相互作用的抗T-BAM（CD40L）抗体，以受体的CD40配体在其表面上带有CD40的平滑肌细胞的活化， 有效抑制细胞的活化。 治疗依赖于CD40配体诱导的含CD40细胞平滑肌细胞活化的病症，特别是炎症性肠病。